By Stephen Nakrosis
GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule.
Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added.
In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years.
Vaccine doses will be ready for use in the U.S. in summer, GSK said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 16, 2025 17:41 ET (21:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。